Second Sight Medical Products (NASDAQ:EYES) released its quarterly earnings data on Wednesday. The medical device company reported ($0.11) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.11), Morningstar.com reports. The company had revenue of $1.77 million for the quarter, compared to analyst estimates of $2.60 million. Second Sight Medical Products had a negative return on equity of 638.26% and a negative net margin of 408.41%.

Shares of Second Sight Medical Products stock opened at $0.76 on Friday. Second Sight Medical Products has a 52 week low of $0.63 and a 52 week high of $2.25. The firm has a market capitalization of $101.24 million, a PE ratio of -1.29 and a beta of 2.20.

Several equities analysts have recently commented on EYES shares. Zacks Investment Research lowered Second Sight Medical Products from a “buy” rating to a “hold” rating in a research note on Tuesday, January 8th. ValuEngine raised Second Sight Medical Products from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd.

A hedge fund recently bought a new stake in Second Sight Medical Products stock. B. Riley Wealth Management Inc. purchased a new stake in Second Sight Medical Products Inc (NASDAQ:EYES) during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 53,500 shares of the medical device company’s stock, valued at approximately $102,000. B. Riley Wealth Management Inc. owned about 0.07% of Second Sight Medical Products as of its most recent SEC filing. Hedge funds and other institutional investors own 9.65% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This story was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this story on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark legislation. The original version of this story can be read at https://theolympiareport.com/2019/03/15/second-sight-medical-products-eyes-issues-earnings-results.html.

About Second Sight Medical Products

Second Sight Medical Products, Inc develops, manufactures, and markets implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals. It focuses on developing new technologies to treat the population of sight-impaired individuals. The company is developing the Orion Visual Cortical Prosthesis, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, or forms of cancer and trauma.

Featured Article: What is the Dow Jones Industrial Average (DJIA)?

Earnings History for Second Sight Medical Products (NASDAQ:EYES)

Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.